[Sustained clinical benefit with sacituzumab govitecan in metastatic triple-negative breast cancer with extensive cutaneous involvement.].

Metastatic triple-negative breast cancer (mTNBC) remains a highly aggressive disease with limited therapeutic options after progression to standard treatments. Together with cutaneous metastases they represent an unmet need in the clinical history of breast cancer patients. We report the case of a patient with recurrent TNBC, initially presenting with nodal relapse and subsequently developing extensive cutaneous involvement. Following progression after chemotherapy combined with immunotherapy, the patient received sacituzumab govitecan as second-line treatment. A significant clinical and metabolic response was documented on serial PET/CT scans, with disease control lasting more than 29 months. This case highlights the clinical benefit of sacituzumab govitecan in heavily pretreated mTNBC, including patients with extensive cutaneous involvement, and supports the growing role of antibody-drug conjugates in reshaping treatment paradigms in advanced disease.